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The potentialities to apply mesenchymal stem cells (MSCs) in regenerative medicine have been extensively studied over the last
decades. In the cardiovascular disease (CVD) field,MSCs-based therapy is the subject of great expectations. Its therapeutic potential
has been already shown in several preclinical models and both the safety and efficacy of MSCs-based therapy are being evaluated
in humans. It is now clear that the predominant mechanism by whichMSCs participate in heart tissue repair is through a paracrine
activity. Via the production of a multitude of trophic factors endowed with different properties, MSCs can reduce tissue injury,
protect tissue from further adverse effects, and enhance tissue repair.The present review discusses the current understanding of the
MSCs secretome as a therapy for treatment of CVD.We provide insights into the possible employment of the MSCs secretome and
their released extracellular vesicles as novel approaches for cardiac regeneration that would have certain advantages over injection
of living cells.
1. Introduction
Cardiovascular diseases (CVD), which are the leading cause
of morbidity and mortality worldwide, account for approx-
imately 30% of all deaths, with nearly half resulting from
myocardial infarction (MI) [1]. Unlike some other organs,
the heart has a limited ability to regenerate, and dysfunction
resulting from significant cardiomyocyte loss under patho-
physiological conditions, such as MI, can lead to heart failure
(HF). Unfortunately, even with the advance in pharmaco-
logical therapies and improvements in mechanical support
devices, for patients with end-stage HF, heart transplantation
remains the main alternative, but the limited availability of
donor organs renders it insufficient.
Adult mesenchymal stem or stromal cells (MSCs) are
nonhematopoietic cells capable of self-renewal and multi-
lineage differentiation into various tissues of mesodermal
origin. They could reside in virtually all postnatal organs
and vascularized tissues [2], but they are mainly found in
bone marrow (BM-MSCs), where they constitute 0.001%–
0.01% of the bone marrow cells. Upon isolation, MSCs are a
heterogeneous cell population characterized by their capacity
to adhere to plastic, develop as fibroblast colony-forming-
units, and differentiate into three cell lineages: osteocytes,
chondrocytes, and adipocytes. After in vitro culture expan-
sion, they are positive for the cell surface markers CD73,
CD90, and CD105 and negative for CD11b, CD14, CD34,
CD45, and human leukocyte antigen- (HLA-) DR [3]. Due
to their multipotency and paracrine effect, MSCs are ideal
candidates for regenerative medicine and immunotherapy
[4].
In the present reviewwe will discuss the literature regard-
ing application of MSCs for cardiac regeneration, presenting
a concise summary about cell-based therapy followed by a
deeper analysis of MSCs paracrine effects via secreted factors
and extracellular vesicle release.
2. Mesenchymal Stem Cells Participate in
Cardiac Repair via Different Mechanisms
Cell-based cardiac repair offers the promise of rebuilding
the injured heart [5]. Mobilization of cells with endogenous
cardiac regenerative potentials, as occurs after injury to other
organs like skeletal muscle and liver, would represent the
ideal strategy to restore cardiac function after MI. Indeed,
there is emerging evidence for a certain level of cardiomy-
ocyte turnover in the mammalian heart. Several types of
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cardiac resident stem cells (CSCs) and cardiac progenitor
cells (CPCs) were isolated and identified in the adult heart,
including c-Kit+ and Sca1+ cells [6]. In general, it has been
proposed that CSCs can differentiate into the three major
heart lineages: myocardial, smooth muscle, and epithelial
cells [7]. The search for CPCs and CSCs that can readily
differentiate within damaged tissue and differentiate into
functioning cardiomyocytes continues with success [8].
Meanwhile, regenerative therapy using bone marrow-
derived mononuclear cells (BM-MNCs) and MSCs has
shown considerable promise. Between 2002 and 2005 the
first stem-cell-based clinical trials for MI initiated using
unfractionated and highly heterogeneous adult BM-MNCs.
Despite initial positive results indicating safety of BM-
MNCs transplantation and some beneficial effects on heart
function, subsequent overall analysis of these first-generation
trials revealed several inconsistencies possibly due to the
differences in trial design, outcome evaluation, and cell
isolation, thereby preventing general conclusions [9] and
sending researchers back to the bench to elucidate strategies
to overcome these limitations [10]. Recent clinical trials have
utilized more homogenous BM-MSCs populations that were
isolated and expanded in culture. Among them, the first
clinical trial for acute MI using human adult MSCs (hMSCs)
was a randomized, double-blind, placebo-controlled, dose-
escalation study of intravenous cell injection that provided
pivotal safety and provisional efficacy data [11].
In order to contribute to cardiovascular repair, in vitro
expanded MSCs can act through different mechanisms.
MSCs can transdifferentiate into cardiomyocytes, as seen
in a study employing female pigs which underwent experi-
mental acute MI and 3 days later received transendocardial
injections of allogeneic male bone marrow-derived MSCs;
cell engraftment and differentiation into cardiomyocytes
and vascular structures were documented [12]. However,
another work showed that there was no evident engraftment
of hMSCs in murine infarcted hearts few weeks after MI
[13]. Accordingly, only about 2% of the administered MSCs
remained localized in the normal pig heart 2 weeks after
coronary infusion and no evidence was obtained indicating
MSC differentiation to cardiomyocytes [14]. In conclusion,
MSCs transdifferentiation into contractile cardiomyocytes
seems to be inefficient [15] and to occur only in the presence
of native cardiomyocytes [16–18].
Another possible mechanism is fusion of MSCs with
native cells, even though this phenomenon was very infre-
quently observed, ruling out any substantial involvement in
MSCs-mediated cardiomyocyte regeneration [16, 19].
MSCs-induced stimulation of endogenous CSCs
via direct cell-cell interaction [16] and MSCs-dependent
paracrine signaling [17, 20] remain two other possible cardiac
regeneration mechanisms. There is still significant debate
about whether MSCs need to engraft at the target site of
injury or can exert their effects systemically. Cell engraftment
might increase the potential for cell-cell contact besides
increasing the release of immunomodulatory and trophic
factors in situ. However, the ischemic microenvironment is
characterized by oxidative stress and inflammation, hostile
conditions that pose a serious problem for MSCs survival.
Experiments in small animals have shown that MSCs do
not persist well inside the graft environment and if there is
or no incorporation into the host tissue, most of the cells
are lost within a month [18]. Failure of MSCs attachment
in the ischemic microenvironment might be exacerbated
by reactive oxygen species- (ROS-) dependent inhibition of
cell adhesion to the extracellular matrix (ECM) components
[21], an event that could hinder the physical interaction of
MSCs with endogenous CSCs.
Thus, a more likely explanation for MSCs-mediated
cardiovascular repair is via exocytosis of a complex secretome
made up of growth factors, cytokines, and other signaling
molecules in the form of both released factors and extracel-
lular vesicles [22], which may generate a microenvironment
suitable to support regenerative processes, induce angiogen-
esis, and protect against further tissue death [23].
The proposal that the paracrine activity of MSCs would
be central for their therapeutic efficacy is supported by recent
preclinical studies demonstrating improved cardiac function
upon infusion of cytokines or conditioned medium (CM)
in the absence of cell transplantation. Figure 1 summarizes
some of the most characterized aspects of cardioprotection
in which MSCs secretome has been involved, and they will
be extended in the following section.
3. Secretome-Based Therapeutic
Efficacy of Mesenchymal Stem Cells for
Cardiovascular Disease
3.1. Released Factors: Cytokines and Growth Factors
3.1.1. Cardiac Tissue Preservation and Remodelling. The first
studies implying paracrine activity ofMSCs as central to their
cardiac therapeutic efficacy date back almost ten years ago
and evidenced trophic, prosurvival, and antiapoptotic effects
(Figure 1).
Among other studies, Takahashi and colleagues assessed
that MSCs-derived cytokines were able to preserve myocar-
dial contractile capacity, inhibit apoptosis of cardiomyocytes,
and allow the formation of new vessels in damaged tissues
[24]. Gnecchi et al. demonstrated that MSCs overexpressing
Akt gene (Akt-MSCs) exposed to hypoxia produced a CM
that was able to prevent death of isolated adult rat ven-
tricular myocytes, as documented by reduced morphologic
evidence of necrosis or apoptosis and attenuated release of
Caspase 3. Moreover, the same CM significantly reduced
infarct size in a rodent infarct model [25]. In the specific
context of MI, Iso et al. [13] compared the gene expression
profiles of cultured hMSCs with those of freshly isolated
CD133+ bone marrow stem cells recently being evaluated
as a candidate cell population for treating MI in patients
[26]. To clarify the implications of the array data, authors
ran ELISAs for several protective secreted factors on serum-
free CM from the hMSCs donor used to treat the infarcted
mice [13]. Results showed that cultured hMSCs expressed
mRNAs for antiapoptotic and matrix-mediating factors, the
majority of them expressed to a greater extent in hMSCs
than in freshly isolated CD133+ cells [13]. In particular,
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Figure 1:The broad repertoire of MSCs secretome has considerable potential for the treatment of CVD. In the context of myocardial protection,
potential therapeutic mechanisms established by MSCs secretome include tissue preservation, angiogenesis, beneficial cardiac remodeling,
anti-inflammatory responses, and finally promotion of endogenous regeneration of the heart. CPCs: cardiac progenitor cells; CSCs: cardiac
stem cells; ECs: endothelial cells; ECM: extracellular matrix.
expression of IL-6 and LIF family members was 40–200-fold
higher. Several mRNAs for matrix-mediating factors, such
as matrix metalloproteinase- (MMP-) 2 and inhibitors such
as (TIMP)-1,2 and matricellular proteins (Thrombospondin-
1 and Tenascin C), were also highly expressed in hMSCs [15].
Overall, the results of microarray analyses demonstrated that
cultured hMSCs expressed mRNAs for a variety of secreted
factors that may be cardioprotective and separative [13].
Follow-up functional genomics studies then revealed that
Secreted Frizzled Related Protein 2 (Sfrp2), a member of
the Wnt signaling pathway, was significantly upregulated in
Akt-MSCs-CM compared to control MSCs and its atten-
uation by siRNA silencing abrogated Akt-MSCs-mediated
cytoprotective effects [27]. Further studies indicated that a
novel secreted protein, hypoxic induced Akt regulated stem
cell factor (HASF), upregulated in Akt-MSCs subjected to
normoxia or hypoxia, maymediate survival effects in isolated
hypoxic cardiomyocytes via PKC-𝜀 signaling by blocking
activation of mitochondrial death channels [28].
In another study it was shown that ablation of TNF recep-
tor 1 (TNFR1) but not TNFR2 in mouseMSCs enhanced pro-
tection following their infusion in the injured myocardium
and correlated with reduced levels of ventricular TNF-𝛼.
Based on this evidence it was postulated thatMSCs paracrine
effects and associated cardioprotection are likely mediated
by TNFR2 [29]. Furthermore, using a swine model of acute
MI, Nguyen et al. have shown that intracoronary injection
of concentrated MSCs-derived growth factors significantly
reduced cardiac troponin-T elevation and improved echocar-
diographic parameters [30].
3.1.2. Angiogenesis. Transplanted MSCs can release soluble
factors contributing to neoangiogenesis inside the heart
(Figure 1). Accordingly, Li et al. demonstrated that GATA-4
overexpression increased both MSCs survival and their
angiogenic potential in the injured myocardium [55]. In
particular, rat BM-MSCs (rMSCs) transduced with GATA-
4 demonstrated increased secretion of proangiogenic factors
and, when transplanted in infarcted rat hearts, these cells
were able to increase blood vessel formation and decrease
infarct size [55]. Furthermore, murine BM-MSCs infected
with the proangiogenic miR-126 showed enhanced expres-
sion of the notch ligand delta-like (Dll)-4, with subse-
quent increased secretion of angiogenic factors and higher
resistance to hypoxia. When these cells were injected in
a murine MI model they displayed increased survival in
the injured tissue, thereby improving cardiac function and
microvessel density [56]. Finally, Timmers et al. collected
hMSCs secretions using a clinically compliant protocol and
intravenous treatment with this CM of a swine model of MI
was found to increase capillary density and preserve cardiac
function, probably by increasing myocardial perfusion [57].
When authors began to evaluate the gene expression profiles
for proteins produced by cultured hMSCs and implicated as
potential angiogenic/arteriogenic factors, secreted cysteine-
rich protein 61 (Cyr61) was found to be a keymolecule for the
observed effects according to immunodepletion experiments
[35]. This protein was also abundantly expressed in the
cellular proteome of murine MSCs as shown by Liquid
Chromatography Mass Spectrometry (LC-MS)/MS, western
blot, and immunofluorescence [35]. These findings suggest
that Cyr 61 has a key role and contribution in promoting
angiogenesis, during regeneration and repair of injured tis-
sues [35].
3.1.3. Immunomodulation. The functional ability of MSCs
to modulate the immune system seems to play a role in
almost all the effects attributed to these cells via three major
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mechanisms: cell-to-cell contact, production of inhibitory
molecules, and induction of regulatory T-cells [58]. MSCs
have been shown to suppress inflammatory reactions in a
variety of different disease states or damaged tissues [17,
59–61] and, interestingly, the proposed mechanisms seem
to be specific for the cause of inflammation. In the case
of a mouse model of induced asthma, for example, MSCs
suppressed Th2-mediated inflammation in a manner that
involved TGF-beta secretion and the activation of IL-4- and
IL-13-induced STAT6 pathway [59], while in the environment
set by interstitial lung disease, inflammation was suppressed
by MSCs through mechanisms involving TNF-alpha and
IL1R [60].
In a mouse model of acute MI inflammation was sup-
pressed through MSCs-dependent production of the anti-
inflammatory factor TNF-𝛼-induced protein 6 (TNAIP6 or
TSG-6); in particular, this molecule was associated with sup-
pression of the excessive inflammatory response consequent
to permanent ligation of the anterior descending coronary
artery (LAD), decrease of the proteolytic damage to the heart
and the subsequent fibrotic scarring, and increase in cardiac
function [17].
3.1.4. Cardiac Endogenous Regeneration. Another recognized
effect of MSCs secretome is the promotion of a regenerative
microenvironment inside the injured tissue (Figure 1), with
direct evidence from studies on MSCs-CM [26, 35, 58]. To
date, several disease models have been used, among them
chronic kidney disease [61], lung [62], and liver injury [63],
demonstrating that MSCs-CM alone is sufficient to mediate
long lasting therapeutic effects.
In the CVD concern, there is strong evidence that MSCs
secrete trophic factors that induce in vitro proliferation of
endogenous CPCs. For example, Nakanishi et al. highlighted
that rMSCs-CM promoted proliferation and migration of
isolated CPCs and prevented their apoptosis when subjected
to hypoxia and serum starvation. Furthermore, conditioned
CPCs also showed upregulated expression of cardiomyocyte-
related genes such as beta-myosin heavy chain (beta-MHC)
and atrial natriuretic peptide (ANP) [64]. Another study
using a hamster model of HF demonstrated a novel nonin-
vasive therapeutic regimen via the direct delivery of MSCs
into the skeletal muscle bed [40]. Intramuscularly injected
MSCs or CM significantly improved ventricular function
1 month after their administration; myocyte regeneration
was evidenced by an approximately twofold increase in
the expression of cell cycle markers (Ki67 and phospho-
histone H3) and an approximately 13% reduction in mean
myocyte diameter. Finally, increased circulating levels of
hepatocyte growth factor (HGF), leukemia inhibitory factor
(LIF), and macrophage colony-stimulating factor (M-CSF)
were associated with the mobilization of c-Kit+, CD31+,
and CD133+ progenitor cells and a subsequent increase
in myocardial c-Kit+ cells [40]. In addition, MSCs secrete
mobilizing factors such as HGF, LIF, SDF-1, SCF, and VE-
Cadherin and, thus, the transplanted MSCs secretome could
also be beneficial for mobilization and homing of host MSCs
[40].
3.2. Extracellular Vesicles. Extracellular vesicles (EVs) is a
term recently proposed by Gyo¨rgy et al. [65] to describe
membrane-limited cellular components, discernible by their
size and composition and released by several cell types.
Current research has focused principally on microvesicles
(MVs) and exosomes, although other vesicular structures
can be secreted, among them microparticles and apoptotic
bodies [65].MVs, initially described in blood [66], have a size
between 100 nm and 1 𝜇m and derive from the detachment
of cytoplasmic protrusions with a process that depends on
the increase of intracellular calcium concentration and subse-
quent enzyme activation (e.g., calpain) and cytoskeleton reor-
ganization. MVs expose high amounts of phosphatidylserine
and specific protein markers, such as integrins, selectins, or
CD40 ligand [67]. On the other hand, exosomes have a size
ranging between 30 and 100 nm and originate upon fusion of
multivesicular endosomes with the plasma membrane.These
vesicles are released by exocytosis [68] by most cell types
including immune cells [69, 70], cancer cells [71], and MSCs
[72]. Their membranes may expose unique proteins that
reflect their cellular source, besides being rich in tetraspanins
(CD9, CD63, and CD81) and heat-shock proteins. Notably,
exosomes can contain numerous proteins and lipids as well
as messenger RNA (mRNA) and microRNAs (miRNAs)
responsible for intercellular signaling.
A recent systematic review on animal studies of various
kinds of injury highlighted that MSC-derived MVs are
strongly associatedwith improved organ function [73]. Initial
demonstrations came from models of renal disease, where
MVs were shown to protect the kidney from toxic injury
by producing factors that limited apoptosis and enhanced
proliferation of endogenous tubular cells [74]. In the context
of CVD, recent studies suggest that the therapeutic effect of
MSCs-derived paracrine action is in large part due to secreted
EVs [75] and exosomes seem to be principally involved in
these effects, as reported by the majority of the literature
data in this concern. In particular, in 2007 Timmers et al.
highlighted that the CM of human embryonic stem cell-
derived MSCs injected in a porcine model of myocardial I/R
was able to limit infarct size and improve systolic function via
probable reduction of TGF-𝛽 signaling and apoptosis [76].
Further fractionation analyses then revealed that marked
cardioprotection was mediated by CM components with a
size between 100 and 220 nm [76]. Subsequentworks from the
same group showed that highly purified exosomes isolated
from CM of the same MSCs had a hydrodynamic radius
of 55–65 nm and induced significant cardioprotection when
injected in a murine MI model [77]. Notably, this effect was
mediated by intact but not lysed exosomes, with specific
increase of ATP levels, Akt and GSK-3𝛽 phosphorylation and
reduction of oxidative stress, phosphorylation of c-Jun, and
inflammatory response in the reperfused myocardium [51].
Besides promising results, however these works do not
underline the precise effectors that mediate protection in
the heart. In this concern, it has been shown that exosomes
can also deliver nucleic acids, like microRNAs (miRNAs). A
recent study showed that preconditioned murine BM-MSCs
released exosomes enriched with miR-22. These vesicles
were highly internalized by cocultured cardiomyocytes and
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prevented their apoptosis via interaction of miR-22 with
methyl CpG binding protein 2 (Mecp2). Finally, delivery of
these enriched exosomes into mice subjected to MI led to
marked reduction of fibrosis [46]. Furthermore, exosomes
derived by rMSCs transduced with GATA-4 contained high
levels of several miRNAs, among them miR-221 and miR-
19a; interestingly, these EVs were able to reduce apoptosis of
ischemic cardiomyocytes via miR-221-dependent inhibition
of p53-upregulated modulator of apoptosis (PUMA), a sub-
class of the Bcl-2 protein family [53], but also via miR-19a-
associated inhibition of PTEN that resulted in activation of
Akt and ERK pathways [45].
Altogether, these data support the assumption that MSC-
dependent paracrine function inside the heart might be due
not only to freely released soluble factors, but also to secreted
exosomes that can deliver a large amount of peptides or other
molecules protecting them from eventual degradation and
facilitating their uptake inside cells. According to previous
findings correlating exosome internalization with microen-
vironmental/intracellular acidity [78], it was proposed that
a mechanism of MSC-derived exosome delivery might be
favoured by low pH typical of ischemic cardiomyocytes
[72]. Furthermore, several authors suggested that MSCs-
exosomes therapy could be more attractive than direct cell
transplantation to treat CVDs, due to avoided surgery-
associated injury or risk of cell differentiation into other cell
types, such as osteoblast or adipocytes or even tumor-like
cells. However, further studies will be needed to elucidate
the specific signaling molecules delivered by exosomes that
subsequently elicit protective mechanisms in the injured
myocardium [28, 72].
4. Secretome Proteomic Profiling
4.1. Released Factors. Due to these encouraging preclinical
results, the MSCs-CM has become a subject of intensive
proteomic profiling, in order to identify the released factors
thatmight be applicable in regenerativemedicine. Analysis of
MSCs secretome was recently enabled mainly for the exten-
sive development in protein separation techniques, mass
spectrometry, immunological methods, and bioinformatics
[79].The in vivo secretome profiling, relying on the analysis of
body fluids or the interstitial solution that directly surrounds
the cells, would seem to most accurately reflect cell secre-
tions in their native microenvironment. In such an in vivo
approach, capillary microdialysis devices or ultrafiltration
probes can be used to collect body fluids [80]. Unfortunately,
MSCs represent only a small subpopulation among the
various cell types within the tissue; thus the analysis of their
secretome inside body fluids or tissue explants is extremely
difficult. Hence, studies of MSCs secretions are currently
performed under in vitro conditions via collection of media
conditioned by cells mostly for 12–48 h of culture [79].
Since 2003, when the first proteomic analysis of human
BM-MSCs secretory counterpart was undertaken [81],
more than 30 additional studies have been published,
showing the growing interest in the MSCs secretome. These
studies have identified numerous candidate modulators
for paracrine effects and cell-mediated/inflammatory
suppression (Table 1). Sarojini et al. published a study in
which secretome derived from mouse stem cell cultures
stimulated chemotaxis of human fibroblasts [34]. 19 secreted
proteins, including ECM structural proteins, collagen
processing enzymes, pigment epithelium-derived factor
(PEDF), and cystatin C, were identified. Interestingly,
PEDF was recognized as one of the most abundant
proteins in the CM; immunodepletion and reconstitution
experiments further revealed that this protein was the
predominant chemoattractant for fibroblasts [34]. Many
studies identified secretion of proangiogenic factors,
including Adrenomedullin [13], Cyr61 [35], and IL-1 [39],
and LV remodelling attenuation was observed through
secretion of factors promoting either vasculogenesis [31, 82]
or endothelial tube formation [33]. Other MSCs secreted
factors promoted mobilization of cardiac stem/progenitor
cells [13, 38] or BM-derived progenitor cells [32, 40];
specifically, Secreted Frizzled Related Protein (SFRP
2) promoted MSC self-renewal and survival [41, 42].
Cardiomyocytes survival improvement was mediated by
at least four different secreted factors [13, 36, 37]. Finally,
anti-inflammatory factors like soluble TNFR1 [43] and
TSG-6 [17] were identified (Table 1).
4.2. Extracellular Vesicles. Isolation of EVs relies on their
purification from supernatants of cells grown in absence of
serum [83] through ultracentrifugation [84], ultrafiltration
[85], or immunoprecipitation technologies using antibody
loaded magnetic cell beads [86]. To date, several thousand
proteins and RNAs have been described in EVs purified from
various cell types or biological fluids (see Table 1 for a selec-
tion of such molecules specifically engaged in cardiovascular
repair).These studies allowed the identification of a common
set of components, mainly associated with the biogenesis or
structure of vesicles or proteins specific for the cell origin or
physiopathological status (for review, see [87]).
EVs from MSCs specifically express CD13, CD29, CD44,
CD73, and CD105 [50, 88, 89] and other surface molecules
that are characteristic of the tissue origin [90]. MSCs-EVs
also contain nucleic acids, both mRNA and noncoding
RNA. The mRNAs present in EVs are representative of the
multiple differentiation and functional properties of MSCs,
including transcripts related to several different cell functions
such as the control of transcription, cell proliferation, and
immune regulation [74, 90]. Among the noncoding RNAs
contained in released MSCs-EVs there are selected patterns
of miRNAs [91, 92], small noncoding RNAs that regulate
gene expression posttranscriptionally by targeting specific
mRNAs. Interestingly, these miRNAs could be subsequently
transferred to target cells [91, 93] and were functionally
active, as evidenced from their ability to downregulate
proteins targeted by selected transferred miRNAs [91, 93–
95]. Gene ontology analysis of the molecules targeted by
the highly expressed miRNAs in MSCs-derived EVs revealed
genes involved in multiorgan development, cell survival, and
differentiation [91].
More recently, Lai et al. [47] focused on the pro-
teome of exosomes to identify candidate proteins or protein
complexes that could drive their therapeutic efficacy in
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Table 1: Summary of molecules released by MSCs, via either direct secretion or exosomes and microvesicles, and their diverse beneficial
effects in cardiovascular repair. The table includes relevant studies demonstrating specific molecule expression/secretion by MSCs and their
respective effects.
Way of secretion Molecule Functional role in cardiovascular repair References
Direct secretion
Adrenomedullin Angiogenic and cardioprotective factor [13]
Angiogenin LV remodeling attenuation through vasculogenesis [31]
Basic fibroblast growth factor (bFGF, FGF-2) Vascular regeneration and attenuation of apoptoticpathways, leading to reduced remodeling [32]
CXCL12 Endothelial tube formation [33]
Cystatin C Fibroblast chemoattraction [34]
Cysteine-rich angiogenic inducer (Cyr61) Angiogenesis promotion [35]
Dickkopf-related proteins (Dkk) JNK signaling activation, eventually resulting incardiomyogenesis [36]
ECM structural proteins Fibroblast chemoattraction [34]
Hepatocyte growth factor (HGF) Mobilization of cardiac progenitor cells [13]
Hypoxic induced Akt regulated stem cell factor
(HASF) Cardiomyocytes survival improvement [37]
Insulin-like growth factor (IGF) Antiapoptotic effect, angiogenesis promotion, andactivation of resident CSCs [38]
Interleukin-1 (IL-1) Angiogenesis promotion [39]
Interleukin-6 (IL-6) VEGF induction [13, 39]
Leukemia inhibitory factor (LIF) Mobilization of BM-progenitor cells andcardioprotection promotion [40]
Pigment epithelium-derived factor (PEDF) Fibroblast chemoattraction [34]
Placental growth factor (PLGF) Prevention of cell death of cardiomyocytes andendothelial cells [13]
Secreted Frizzled Related Protein (SFRP 2) Fibrosis and apoptosis reduction, promotion of MSCself-renewal and engraftment [41, 42]
Soluble TNFR1 (sTNFR1) Inflammatory response attenuation [43]
Stem cell-derived factor (SDF-1) Stem cell recruitment and cardiomyocyte and MSCsurvival [32, 44]
TNF-𝛼 stimulated gene-6 (TSG-6) Anti-inflammation action [17]
Vascular endothelial growth factor (VEGF) Prevention of cell death of cardiomyocytes andendothelial cells [13]
Exosomes
miR-19a Akt/ERK signaling activation, through PTEN targeting [45]
miR22 Apoptosis reduction and ischemic CMCs injuryimprovement, through Mecp2 targeting [46]
20S proteasome subunits (PMSA 1-7) Cardioprotection through proteolytic degradation ofmisfolded proteins [47]
Unknown PMEC migration and vascularization improvement [48]
Unknown Angiogenesis promotion [49]
Unknown VEGF level incensement and angiogenesis promotion [50]
Unknown Oxidative stress inhibition, PI3K/Akt pathwayactivation and inflammatory activity reduction [51]
Unknown Hypoxic signal pathway inhibition [52]
Microvesicles miR221
CMCs apoptosis reduction and CMCs survival
improvement [53]
Unknown Endothelial cell proliferation and blood flow recovery [54]
ameliorating myocardial I/R injury in a mouse model of
MI. Clustering of these proteins according to their functions
had suggested that MSCs exosomes have the potential to
drive many biological processes, an observation consistent
with the reported efficacy of MSCs in treating a myriad
of diseases encompassing as cardiovascular (e.g., acute
myocardial infarction, end-stage ischemic heart disease, or
prevention of vascular restenosis) and noncardiovascular
diseases [96]. The proteome of MSCs exosomes obtained
by three independent experiments and analysed by mass
spectrometry and cytokine array identified 857 proteins
that were distributed over a wide array of biochemical and
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cellular processes such as communication, structure and
mechanics, inflammation, exosome biogenesis, tissue repair,
and metabolism [96].
In some studies the specific exosome-contained molecu-
les able tomediate the protective effects onmyocardiumwere
identified: miR-19a promoted the cardioprotective Akt/ERK
signaling [45], miR22 reduced apoptosis and improved
ischemic injury [46], and 20S proteasome subunits exerted
cardioprotection through degradation of misfolded proteins
[47] (Table 1). In other cases, angiogenesis promotion [48–
50], oxidative stress inhibition [51], and hypoxic signal
pathway inhibition [52] were recognized as cardioprotective
functions contained in MSCs exosomes, yet the responsible
molecules have not been identified yet (Table 1).
Finally, MSCs microvesicles were found to improve car-
diomyocytes survival through miR221 [53] and to increase
endothelial cell proliferation and blood flow recovery [54]
(Table 1).
5. Conclusions
Regenerative medicine is a subject of great expectations
and gives rise to enormous hopes for patients who display
severe forms of diseases without effective treatment. In the
CVD field, MSCs-based therapy might be an advantageous
alternative to current approaches and in the last decade, its
potential has been demonstrated in numerous preclinical
studies and it is being evaluated in clinics with promising
results. Interestingly, the potential of MSCs to contribute
to tissue repair has been found largely dependent on their
secretory capacity (Figure 1) rather than their differentiation
capacity. Thus far research has mostly focused on the secre-
tion of cytokines and growth factors by MSCs. However,
recent data suggests that the therapeutic effect of MSCs
secretome can be partly due to secreted EVs, which can
mirror the phenotype of their parent cells.
Therefore, the employment of cell-derived secretome to
replace stem cells transplantation is of enormous interest.
While MSCs are considered relatively safe, the development
of therapeutic strategies that may avoid administration of
living stem cells will attenuate the safety concerns relative
to cell origin and immunocompatibility issues. A secretome-
based approach should also minimise biological variability,
allow precise dosing, and thus lead to the development of safe
and effective therapeutic strategies with possibly predictable
outcomes. Another advantage is the possibility of avoiding
the lung barrier, one of the major obstacles for systemic
administration of MSCs. Finally, given that patients with
HF are at an increased surgical risk, the development of a
noninvasive therapeutic approach looks very appealing.
In this perspective, the possibility of harnessing theMSCs
secretome (both soluble factors and EVs) would have certain
advantages over administration of a single factor that cannot
mimic the actions of MSCs. Several questions have however
to be addressed before clinical use can be considered.
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